Rejection, Transplant Completed Phase 2 Trials for Alemtuzumab (DB00087)

Also known as: Transplant Rejection / Transplant rejections / Graft Rejection

IndicationStatusPhase
DBCOND0030946 (Rejection, Transplant)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00001984Effectiveness of the Investigational Drug Campath-1H in Preventing Rejection of Transplanted KidneysTreatment